Skip to main content Accessibility help
×
Home
  • Print publication year: 2011
  • Online publication date: November 2011

3 - The function of the endocannabinoid system

Related content

Powered by UNSILO

References

Ahlskog, J.E. (2001) Parkinson’s disease: medical and surgical treatment. Neurol Clin, 19: 579–605.
Al-Hayani, A., Wease, K.N., Ross, R.A., et al. (2001) The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology, 41:1000–5.
Baker, D., Jackson, S.J. and Pryce, G. (2007) Cannabinoid control of neuroinflammation related to multiple sclerosis. Brit J Pharmacol, 152:649–54.
Baker, D., Pryce, G., Croxford, J.L., et al. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB Journal, 15:300–2.
Battista, N., Pasquariello, N., Di Tommaso, M., et al. (2008) Interplay between endocannabinoids, steroids and cytokines in the control of human reproduction. J Neuroendocrinol, 20:82–9.
Bensaid, M., Gary-Bobo, M., Esclangon, A., et al. (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol, 63:908–14.
Bisogno, T., Howell, F., Williams, G., et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol, 163:463–8.
Bisogno, T., Ortar, G., Petrosino, S., et al. (2009) Development of a potent inhibitor of 2-arachidonoyl glycerol hydrolysis with antinociceptive activity in vivo. Biochim Biophys Acta, 1791:53–60.
Blankman, J.L., Simon, G.M. and Cravatt, B.F. (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoyl glycerol. Chemistry and Biology, 14:1347–56.
Bortolato, M., Campolongo, P., Mangieri, R.A., et al. (2006) Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology, 31:2652–9.
Chevaleyre, V. and Castillo, P.E. (2003) Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron, 38:461–72.
Cobellis, G., Cacciola, G., Scarpa, D., et al. (2006) Endocannabinoid system in frog and rodent testis: type-1 cannabinoid receptor and fatty acid amide hydrolase activity in male germ cells. Biol Reprod, 75:82–9.
Comelli, F., Giagnoni, G., Bettoni, I., et al. (2007) The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Brit J Pharmacol, 152:787–94.
Cota, D. (2008) Role of the endocannabinoid system in energy balance regulation and obesity. In Obesity and Metabolism, Korbonits, M. (ed), Basel: Karger, pp.135–45.
de Lago, E., Ligresti, A., Ortar, G., et al. (2004) In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur J Pharmacol, 484:249–57.
De Petrocellis, L., Cascio, M.G. and Di Marzo, V. (2004) The endocannabinoid system: a general view and latest additions. Brit J Pharmacol, 141:765–74.
De Petrocellis, L., Starowicz, K., Moriello Schiano, A., et al. (2007) Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB1 receptors and endovanilloids. Exp Cell Res, 313:1911–20.
Després, J.P. (2009) Pleiotropic effects of rimonabant: clinical implications. Curr Pharm Des, 15:553–70.
Devane, W.A., Dysarz, F.A., Johnson, M.R., et al. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol, 34:605–13.
Devane, W.A., Hanuš, L., Breuer, A., et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258:1946–9.
Di Marzo, V. (1998) ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta, 1392:153–75.
Di Marzo, V. (2008) The endocannabinoid system in obesity and type 2 diabetes. Diabetologia, 51:1356–67.
Di Marzo, V., Bisogno, T. and De Petrocellis, L. (2001) Anandamide: some like it hot. Trends Pharmacol Sci, 22:346–9.
Di Marzo, V. and Deutsch, D.G. (1998) Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis, 5:386–404.
Diana, M.A., Levenes, C., Mackie, K., et al. (2002) Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J Neurosci, 22:200–8.
Diana, M.A. and Marty, A. (2004) Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Brit J Pharmacol, 142:9–19.
ElSohly, M.A. and Slade, D. (2005) Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sciences, 78:539–48.
Fernández-Ruiz, J. (2009) The endocannabinoid system as a target for the treatment of motor dysfunction. Brit J Pharmacol, 156:1029–40.
Garcia, C., Paloma-Garo, C., Garcia-Arencibia, M., et al. (2011) Symptom-relieving and neuro protective, effects of the phytocannabinoid Δ9 - THCV in animal models of Parkinson’s Disease. Br J Pharmacol, 163: 1495–1506.
Gerdeman, G.L. (2008) Endocannabinoids at the synapse: retrograde signaling and presynaptic plasticity in the brain. In Köfalvi, A. (ed). Cannabinoids and the Brain, New York: Springer Science+Business Media, pp.203–56.
Gerdeman, G.L., Ronesi, J. and Lovinger, D.M. (2002) Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci, 5:446–51.
Gong, J.-P., Onaivi, E.S., Ishiguro, H., et al. (2006) Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res, 1071:10–23.
Guindon, J. and Hohmann, A. G. (2008) Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Brit J Pharmacol, 153:319–34.
Haller, J., Bakos, N., Szirmay, M., et al. (2002) The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci, 16:1395–8.
Haller, J., Varga, B., Ledent, C., et al. (2004) CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol, 15:299–304.
Hansen, H.S., Lauritzen, L., Moesgaard, B., et al. (1998) Formation of N-acyl-phosphatidylethanolamines and N-acylethanolamines – proposed role in neurotoxicity. Biochem Pharmacol, 55:719–25.
Hanuš, L., Abu-Lafi, S., Fride, E., et al. (2001) 2-arachidonoyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA, 98:3662–5.
Hanuš, L.O. (2007) Discovery and isolation of anandamide and other endocannabinoids. Chem Biodivers, 4:1828–41.
Hao, S., Avraham, Y., Mechoulam, R., et al. (2000) Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol, 392:147–56.
Hemmer, B., Archelos, J.J. and Hartung, H.P. (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci, 3:291–301.
Herkenham, M., Lynn, A.B., Johnson, M.R., et al. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci, 11:563–83.
Hill, M.N., Hillard, C.J., Bambico, F.R., et al. (2009) The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci, 30:484–93.
Horn, S. and Stern, M.B. (2004) The comparative effects of medical therapies for Parkinson’s disease. Neurology, 63: S7–S12.
Howlett, A.C. (2002) The cannabinoid receptors. Prostag Oth Lipid M, 68–9:619–31.
Howlett, A.C. (2005) Cannabinoid receptor signaling. In Pertwee, R.G. (ed), Cannabinoids (Handbook of Experimental Pharmacology) 168, Heidelberg: Springer-Verlag, pp.53–79.
Huang, S.M., Bisogno, T., Trevisani, M., et al. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA, 99:8400–5.
Jamshidi, N. and Taylor, D.A. (2001) Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Brit J Pharmacol, 134:1151–4.
Jayamanne, A., Greenwood, R., Mitchell, V.A., et al. (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Brit J Pharmacol, 147:281–8.
Kozak, K.R., Rowlinson, S.W. and Marnett, L.J. (2000) Oxygenation of the endocannabinoid, 2-arachidonoylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem, 275:33744–9.
Lang, A.E. and Lozano, A.M. (1998) Parkinson’s disease. Second of two parts. New Engl J Med, 339:1130–43.
Liu, J., Wang, L., Harvey-White, J., et al. (2006). A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA, 103:13345–50.
Long, J.Z., Nomura, D.K. and Cravatt, B.F. (2009) Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol, 16:744–53.
Maccarrone, M. (2008) CB2 receptors in reproduction. Brit J Pharmacol, 153:189–98.
Maccarrone, M., Barboni, B., Paradisi, A., et al. (2005) Characterization of the endocannabinoid system in boar spermatozoa and implications for sperm capacitation and acrosome reaction. J Cell Sci, 118:4393–404.
Maccarrone, M., Cecconi, S., Rossi, G., et al. (2003). Anandamide activity and degradation are regulated by early postnatal aging and follicle-stimulating hormone in mouse sertoli cells. Endocrinology, 144:20–28.
Maione, S., De Petrocellis, L., de Novellis, V., et al. (2007) Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Brit J Pharmacol, 150:766–81.
Martin, M., Ledent, C., Parmentier, M., et al. (2002) Involvement of CB1 cannabinoid receptors in emotional behavior. Psychopharmacology, 159:379–87.
Matias, I. and Di Marzo, V. (2007) Endocannabinoids and the control of energy balance. Trends Endocrin Met, 18:27–37.
Matias, I., Gonthier, M.P., Orlando, P., et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocr Metab, 91:3171–80.
Matsuda, L.A., Lolait, S.J., Brownstein, M.J., et al. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346:561–4.
Mechoulam, R., Ben-Shabat, S., Hanuš, L., et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol, 50:83–90.
Mechoulam, R., Feigenbaum, J.J., Lander, N., et al. (1988) Enantiomeric cannabinoids – stereospecificity of psychotropic activity. Experientia, 44:762–4.
Mechoulam, R. and Gaoni, Y. (1965) A total synthesis of dl-Δ1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc, 87:3273–5.
Mechoulam, R., Lander, N., Varkony, T.H., et al. (1980) Stereochemical requirements for cannabinoid activity. J Med Chem, 23:1068–72.
Mechoulam, R. and Shvo, Y. (1963) The structure of cannabidiol. Tetrahedron, 19:2073–8.
Munro, S., Thomas, K.L. and Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365:61–5.
Navarro, M., Hernández, E., Muñoz, R.M., et al. (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport, 8:491–6.
Nissen, S.E., Nicholls, S.J., Wolski, K., et al. (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease. The STRADIVARIUS randomized controlled trial. J Am Med Assoc, 299:1547–60.
Onaivi, E.S., Ishiguro, H., Gong, J.P., et al. (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci, 1074:514–36.
Osei-Hyiaman, D., DePetrillo, M., Pacher, P., et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest, 115:1298–305.
O’Sullivan, S.E. (2007) Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Brit J Pharmacol, 152:576–82.
Oz, M. (2006) Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol Therapeut, 111:114–44.
Pagotto, U., Marsicano, G., Cota, D., et al. (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev, 27:73–100.
Perez, J. and Ribera, M.V. (2008) Managing neuropathic pain with Sativex®: a review of its pros and cons. Expert Opin Pharmacotherapy, 9:1189–95.
Pertwee, R.G. (2001) Cannabinoid receptors and pain. Prog Neurobiol, 63:569–611.
Pertwee, R.G. (2005) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. The AAPS Journal, 7:E625–E654.
Pertwee, R.G. (2006a) Cannabinoid pharmacology: the first 66 years. Brit J Pharmacol, 147:S163–S171.
Pertwee, R.G. (2006b) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes, 30:S13–S18.
Pertwee, R.G. (2007) Cannabinoids and multiple sclerosis. Mol Neurobiol, 36:45–59.
Pertwee, R.G. (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Brit J Pharmacol, 153:199–215.
Pertwee, R.G. (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Brit J Pharmacol, 156:397–411.
Pertwee, R.G. (2010) Receptors targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem, 17:1360–81.
Pertwee, R.G. and Ross, R.A. (2002) Cannabinoid receptors and their ligands. Prostag Leukotr Ess, 66:101–21.
Pertwee, R.G. and Thomas, A. (2009) Therapeutic applications for agents that act at CB1 and CB2 receptors. In Reggio, P.H. (ed), The Cannabinoid Receptors, New York: Humana Press, pp. 361–92.
Petrosino, S. and Di Marzo, V. (2010) FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Current Opinion in Investigational Drugs, 11:51–62.
Pinsger, M., Schimetta, W., Volc, D., et al. (2006) Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain – a randomized controlled trial. Wien Klin Wochenschr, 118: 327–35.
Porter, A.C., Sauer, J.-M., Knierman, M.D., et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther, 301:1020–4.
Pryce, G., Ahmed, Z., Hankey, D.J.R., et al. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 126:2191–202.
Rahn, E.J. and Hohmann, A.G. (2009) Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics, 6:713–37.
Ravinet Trillou, C., Arnone, M., Delgorge, C., et al. (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol-Reg I, 284:R345–R353.
Ravinet Trillou, C., Delgorge, C., Menet, C., et al. (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int Jour Obes, 28:640–8.
Riedel, G., Fadda, P., McKillop-Smith, S., et al. (2009) Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Brit J Pharmacol, 156:1154–66.
Robbe, D., Kopf, M., Remaury, A., et al. (2002) Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. P Natl Acad Sci USA, 99:8384–8.
Rodríguez de Fonseca, F., Del Arco, I., Bermudez-Silva, F.J., et al. (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcoholism, 40:2–14.
Rodriguez-Oroz, M.C., Jahanshahi, M., Krack, P., et al. (2009) Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. The Lancet Neurology, 8:1128–39.
Romero, J., Berrendero, F., Pérez-Rosado, A., et al. (2000) Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci, 66:485–94.
Ross, R.A. (2009) The enigmatic pharmacology of GPR55. Trends Pharmacol Sci, 30:156–63.
Russo, R., LoVerme, J., La Rana, G., et al. (2007) Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-α receptor agonist GW7647. Eur J Pharmacol, 566:117–9.
Rutkowska, M., Jamontt, J. and Gliniak, H. (2006) Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep, 58:200–6.
Salamone, J.D., McLaughlin, P.J., Sink, K., et al. (2007) Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav, 91:383–8.
Sastre-Garriga, J., Vila, C., Clissold, S., et al. (2011) THC and CBD oromucosal spray (Sativex®) in the management of spasicity associated with multiple sclerosis. Expert Rev Neurother, 11: 627–637.
Schmid, H.H., Schmid, P.C. and Natarajan, V. (1990) N-acylated glycerophopholipids and their derivatives. Prog Lipid Res, 29:1–43.
Schmid, H.H.O. and Berdyshev, E.V. (2002) Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostag Leukotr Ess, 66:363–76.
Schmid, H.H., Schmid, P.C. and Natarajan, V. (1996) The N-acylation-phosphodiesterase pathway and cell signalling. Chem Phys Lipids, 80:133–42.
Schmid, P.C., Reddy, P.V., Natarajan, V., et al. (1983) Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase-D type. The J Biol Chem, 258:9302–6.
Schuel, H., Burkman, L.J., Lippes, J., et al. (2002) N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids, 121:211–27.
Simon, G.M. and Cravatt, B.F. (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for α/β-hydrolase 4 in this pathway. J Biol Chem, 281:26465–72.
Skrabek, R.Q., Gallmova, L., Ethans, K., et al. (2008) Nabilone for the treatment of pain in fibromyalgia. The Journal of Pain, 9:164–73.
Smart, D., Gunthorpe, M.J., Jerman, J.C., et al. (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Brit J Pharmacol, 129:227–30.
Stella, N., Schweitzer, P. and Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388:773–8.
Sugiura, T., Kobayashi, Y., Oka, S., et al. (2002) Biosynthesis and degradation of anandamide and 2- arachidonoyl glycerol and their possible physiological significance. Prostag Leukotr Ess, 66:173–92.
Sugiura, T., Kondo, S., Sukagawa, A., et al. (1995) 2-Arachidonoyl glycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Co, 215:89–97.
Sun, Y.X., Tsuboi, K., Okamoto, Y., et al. (2004) Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J, 380:749–56.
Ueda, N., Yamanaka, K., Terasawa, Y., et al. (1999) An acid amidase hydrolyzing anandamide as an endogenous ligand for cannabinoid receptors. FEBS Letters, 454:267–70.
Urigüen, L., Pérez-Rial, S., Ledent, C., et al. (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology, 46:966–73.
Van Sickle, M.D., Duncan, M., Kingsley, P.J., et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 310:329–32.
Vickers, S.P., Webster, L.J., Wyatt, A., et al. (2003) Preferential effects of the cannabinoid CB1, receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology, 167:103–11.
Wang, H.B., Xie, H.R., Sun, X.F., et al. (2007) Differential regulation of endocannabinoid synthesis and degradation in the uterus during embryo implantation. Prostag Oth Lipid M, 83:62–74.
Wei, B.Q.Q., Mikkelsen, T.S., McKinney, M.K., et al. (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem, 281:36569–78
Wiley, J.L., Burston, J.J., Leggett, D.C., et al. (2005) CB1 cannabinoid receptor-mediated modulation of food intake in mice. Brit J Pharmacol, 145:293–300.
Williams, C.M. and Kirkham, T.C. (1999) Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology, 143:315–7.
Williams, C.M. and Kirkham, T.C. (2002) Reversal of Δ9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Be, 71:341–348.
Williams, C.M., Rogers, P.J. and Kirkham, T.C. (1998) Hyperphagia in pre-fed rats following oral Δ9-THC. Physiol Behav, 65:343–6.
Wilson, R.I., Kunos, G. and Nicoll, R.A. (2001) Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron, 31:453–62.
Wilson, R.I. and Nicoll, R.A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 410:588–92.
Wilson, R.I. and Nicoll, R.A. (2002) Neuroscience – endocannabinoid signaling in the brain. Science, 296:678–82.
Yates, M.L. and Barker, E.L. (2009) Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoyl glycerol. Mol Pharmacol, 76:11–17.
Yu, M., Ives, D. and Ramesha, C.S. (1997) Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem, 272:21181–6.
Zygmunt, P.M., Petersson, J., Andersson, D.A., et al. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400:452–7.